The FDA has approved Onyda XR, a new treatment option for ADHD in pediatric patients aged 6 and above. This is the first and only liquid nonstimulant for ADHD. It can be used as a monotherapy or as an adjunctive therapy to an approved central nervous system stimulant.
The mental health crisis in the United States continues to worsen, with suicide being the second leading cause of death among college athletes. This alarming trend underscores the importance of mental health awareness, which is being observed this month as Mental Health Awareness Month.
Researchers have found that Psilocybin treatment shows promise in treating PTSD. In a Phase 2 study, Compass Pathways’ investigational COMP360 demonstrated durable improvements in CAPS-5 and SDS total scores compared to baseline with a single dose.
Exercise and mindfulness are being explored as potential treatments for depression and substance misuse. Researchers are delving into novel treatments and underlying causes of mental health disorders.
A long-acting subcutaneous olanzapine injection, known as TEV-749, has shown positive efficacy results in treating certain mental health conditions. The drug demonstrated statistically significant and clinically meaningful results in clinical trials.
In August 2023, zuranolone (Zurzuvae) was approved by the FDA as an oral treatment for adults with postpartum depression (PPD). This marks the first FDA-approved pill for the treatment of PPD in adults, providing new hope for those struggling with this mental health condition.